Stocks
Haemonetics Corporation Financial Statements (HAE) |
||||||||||
| Haemonetics Corporationsmart-lab.ru | % | 2022 | 2023 | 2023 | 2024 | 2024 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 25.05.2022 | 31.03.2023 | 22.05.2023 | 31.03.2024 | 20.05.2024 | 07.11.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 993.2 | 1 169 | 1 169 | 1 309 | 1 368 | ||||
| Operating Income, bln rub | 80.8 | 156.0 | 156.0 | 164.9 | 181.3 | |||||
| EBITDA, bln rub | ? | 178.5 | 249.3 | 249.3 | 262.1 | 265.7 | ||||
| Net profit, bln rub | ? | 43.4 | 115.4 | 115.4 | 117.6 | 112.9 | ||||
| OCF, bln rub | ? | 172.3 | 273.1 | 273.1 | 181.8 | 149.6 | ||||
| CAPEX, bln rub | ? | 96.5 | 110.2 | 110.2 | 66.3 | 278.3 | ||||
| FCF, bln rub | ? | 75.8 | 162.9 | 162.9 | 115.5 | -128.7 | ||||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0 | |||||
| OPEX, bln rub | 433.8 | 459.1 | 459.1 | 526.7 | 526.6 | |||||
| Cost of production, bln rub | 487.7 | 553.6 | 553.6 | 632.5 | 660.4 | |||||
| R&D, bln rub | 46.8 | 50.1 | 50.1 | 54.4 | 60.8 | |||||
| Interest expenses, bln rub | 17.1 | 14.6 | 14.6 | 13.0 | 27.0 | |||||
| Assets, bln rub | 1 860 | 1 935 | 1 935 | 2 196 | 2 196 | 2 525 | ||||
| Net Assets, bln rub | ? | 749.4 | 818.0 | 818.0 | 960.0 | 960.0 | 878.9 | |||
| Debt, bln rub | 773.6 | 765.9 | 765.9 | 807.8 | 807.8 | 1 225 | ||||
| Cash, bln rub | 259.5 | 284.5 | 284.5 | 178.8 | 178.8 | 299.3 | ||||
| Net debt, bln rub | 514.1 | 481.4 | 481.4 | 629.0 | 629.0 | 925.7 | ||||
| Ordinary share price, rub | 63.9 | 82.8 | 82.8 | 85.4 | 85.4 | 85.4 | ||||
| Number of ordinary shares, mln | 51.0 | 0.000 | 50.8 | 50.7 | 50.9 | |||||
| Market cap, bln rub | 3 259 | 0 | 4 202 | 0 | 4 328 | 4 345 | ||||
| EV, bln rub | ? | 3 773 | 481 | 4 684 | 629 | 4 957 | 5 270 | |||
| Book value, bln rub | -28 | 76 | 76 | -11 | -11 | -225 | ||||
| EPS, rub | ? | 0.85 | 2.27 | 2.32 | 2.22 | |||||
| FCF/share, rub | 1.48 | 3.21 | 2.28 | -2.53 | ||||||
| BV/share, rub | -0.55 | 1.50 | -0.22 | -4.42 | ||||||
| EBITDA margin, % | ? | 18.0% | 21.3% | 21.3% | 20.0% | 19.4% | ||||
| Net margin, % | ? | 4.37% | 9.87% | 9.87% | 8.98% | 8.25% | ||||
| FCF yield, % | ? | 2.32% | 0.00% | 3.88% | 0.00% | 2.67% | -2.96% | |||
| ROE, % | ? | 5.79% | 14.1% | 14.1% | 0.00% | 12.2% | 12.9% | |||
| ROA, % | ? | 2.33% | 5.96% | 5.96% | 0.00% | 5.35% | 4.47% | |||
| P/E | ? | 75.1 | 0.00 | 36.4 | 36.8 | 38.5 | ||||
| P/FCF | 43.0 | 0.00 | 25.8 | 37.5 | -33.7 | |||||
| P/S | ? | 3.28 | 0.00 | 3.60 | 3.31 | 3.18 | ||||
| P/BV | ? | -115.9 | 0.00 | 55.3 | 0.00 | -385.0 | -19.3 | |||
| EV/EBITDA | ? | 21.1 | 1.93 | 18.8 | 18.9 | 19.8 | ||||
| Debt/EBITDA | 2.88 | 1.93 | 1.93 | 2.40 | 3.48 | |||||
| R&D/CAPEX, % | 48.5% | 45.5% | 45.5% | 82.1% | 21.9% | |||||
| CAPEX/Revenue, % | 9.72% | 9.43% | 9.43% | 5.06% | 20.3% | |||||
| Haemonetics Corporation shareholders | ||||||||||
